Amgen’s $13.4 billion Otezla purchase shows, once more, the direct financial value of IP in the life sciences space

The Californian company cites US patent protection until 2028 as a key driver of the psoriasis drug acquisition, but antitrust concerns remain


Get unlimited access to all IAM content